|
CYLD expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.70041758451589E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.81521464526213E-12 |
| Normal-vs-Stage2 |
2.93409740947936E-11 |
| Normal-vs-Stage3 |
2.22044604925031E-16 |
| Normal-vs-Stage4 |
1.64823710235851E-12 |
| Stage1-vs-Stage2 |
7.998400E-01 |
| Stage1-vs-Stage3 |
4.689800E-01 |
| Stage1-vs-Stage4 |
1.344230E-01 |
| Stage2-vs-Stage3 |
8.058600E-01 |
| Stage2-vs-Stage4 |
3.393400E-01 |
| Stage3-vs-Stage4 |
4.309800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.73161485150786E-12 |
| Normal-vs-AfricanAmerican |
1.05390000004757E-06 |
| Normal-vs-Asian |
3.51940698806175E-14 |
| Caucasian-vs-AfricanAmerican |
3.723400E-01 |
| Caucasian-vs-Asian |
2.572200E-01 |
| AfricanAmerican-vs-Asian |
1.019990E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.65456537359887E-12 |
| Normal-vs-Female |
1.46105350040671E-13 |
| Male-vs-Female |
3.128000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.92434956858278E-12 |
| Normal-vs-Age(41-60Yrs) |
1.49547041417009E-13 |
| Normal-vs-Age(61-80Yrs) |
3.17523785042795E-14 |
| Normal-vs-Age(81-100Yrs) |
1.501970E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.096200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.884400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.950600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.819800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.414400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.409800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.780600E-01 |
| Classical-VS-Follicular |
9.351800E-02 |
| Classical-VS-Other |
5.050300E-02 |
| Classical-VS-Normal |
3.97859523104671E-12 |
| Tall-VS-Follicular |
9.881200E-01 |
| Tall-VS-Other |
1.712370E-01 |
| Tall-VS-Normal |
6.59829968441272E-11 |
| Follicular-VS-Other |
2.072000E-01 |
| Follicular-VS-Normal |
1.62525548574877E-12 |
| Other-VS-Normal |
1.73250000012892E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.66155977865401E-12 |
| Normal-vs-N1 |
1.626032641866E-12 |
| N0-vs-N1 |
1.001580E-01 |
|
|
